Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Breast tumor kinase (BRK)/protein tyrosine kinase 6 is overexpressed in approximately 80% of breast cancers.
• BRK plays key oncogenic roles in breast cancer cell proliferation, survival, and migration.
• Targeting BRK remains an underexplored therapeutic strategy for breast cancer.

Purpose of the Study:

• To discover a new class of potent and selective BRK inhibitors.
• To evaluate the therapeutic potential of novel BRK inhibitors in preclinical models of breast cancer.

Main Methods:

• A parallel compound-centric approach was employed to identify BRK inhibitors.
• In vitro assays assessed kinase inhibition and effects on cancer cell proliferation.
• In vivo efficacy was evaluated using mouse xenograft models.
• Combination studies with HER2 inhibitors and ER blockade were performed.

Main Results:

• XMU-MP-2 was identified as a potent and selective BRK inhibitor.
• XMU-MP-2 demonstrated target-specific inhibition of BRK kinase activity.
• Inhibition of BRK signaling by XMU-MP-2 reduced proliferation in BRK-positive breast cancer cells.
• XMU-MP-2 repressed tumor growth in mouse xenograft models.
• XMU-MP-2 showed synergistic effects with HER2 inhibitors and ER blockade.

Conclusions:

• The findings provide a preclinical proof of concept for targeting BRK kinase in breast cancer.
• XMU-MP-2 represents a promising pharmaceutical agent for breast cancer therapy.
• Combination therapies involving BRK inhibition may enhance treatment efficacy.